US Bio CEO Transfers $700 Million in Stock to Relatives and Cashes Out $1 Billion Deal

Between March 23 and 26, Protagonist Therapeutics, Inc. (NASDAQ: PTGX) disclosed that its CEO and CFO executed a series of stock option exercises, intra-family share gifts, and multi-million-dollar share sales.

On March 23, CEO Dinesh V. Patel gifted 50,000 common shares to a family member at no cost. At a recent trading price of $101 per share, that stake is valued at approximately $5.05 million (about KRW 7 billion). On March 24 and 25, he exercised roughly 50,000 vested stock options at $8.58 per share and then sold the same number of shares in cashless transactions at $101 per share, disposing of about $5.5 million (around KRW 7.5 billion) while still maintaining a direct holding of approximately 520,000 shares.

On March 26, CFO Asif Ali exercised two option grants to acquire about 24,700 shares and immediately sold them at roughly $104 per share, monetizing around $2.58 million (approximately KRW 3.5 billion). Following the transactions, his direct holdings rose to about 60,750 shares, with a market value near $6.3 million (around KRW 8.5 billion).

The company’s stock recently spiked after the U.S. Food and Drug Administration approved Icotyde—an oral peptide therapy for moderate-to-severe plaque psoriasis co-developed with Johnson & Johnson—on March 18, triggering a $50 million (about KRW 67.5 billion) milestone payment and securing future sales royalties.

Also on March 26, board director Selick sold 24,000 common shares at $105 per share, realizing approximately $2.52 million (around KRW 3.4 billion), marking another round of insider sales by management and directors.

Protagonist Therapeutics is a U.S. biotech firm developing oral peptide-based therapies for hematological and immune-inflammatory diseases. Its platform technology converts mechanisms traditionally limited to injectables into pill form. Through its partnership with Johnson & Johnson, the company is co-developing Icotyde for psoriasis and rusfertide for polycythemia vera. Icotyde’s FDA approval and rusfertide’s priority review have positioned this alliance as a flagship Big Pharma–biotech collaboration in the U.S. for 2026.